RVMD
USDRevolution Medicines Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$57.990
Kõrge
$59.680
Madal
$57.740
Maht
2.37M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
10.9B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.19M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77
RBC Capital analyst Leonid Timashev initiates coverage on Revolution Medicines with a Outperform rating and announces Price Target of $77.
Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today
Mizuho Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $90
Mizuho analyst Joseph Catanzaro initiates coverage on Revolution Medicines with a Outperform rating and announces Price Target of $90.
Seotud aktsiad
HTIA
Healthcare Trust Inc. 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock
FLD
FTAC Emerald Acquisition Corp.
SNDX
Syndax Pharmaceuticals Inc.
ACST
Acasti Pharma Inc.
CEVA
CEVA Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.